Hi there!
We track 52,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!
PostEra
PostEra uses its AI platform Proton to speed up the discovery and optimization of small-molecule drug candidates for biopharma partners and internal programs. Proton is an end-to-end machine learning…
PostEra
PostEra uses its AI platform Proton to speed up the discovery and optimization of small-molecule drug candidates for biopharma partners and internal programs. Proton is an end-to-end machine learning…
TL;DR
What they do: AI-driven drug discovery using Proton, an ML platform for medicinal chemistry
Business model: B2B SaaS and partnership-led co-discovery collaborations plus internal drug programs
Founded: 2019
Funding (reported): $26M total equity/grant financing reported
Key partners: Multi-year collaborations with Pfizer and Amgen; NIH funding
Company Overview
Problem Domain
Small-molecule drug discovery and optimization (medicinal chemistry).
Founded
2019
Industry
Biotechnology Research
Funding Track Record
$24M
Announced alongside a strategic collaboration with Pfizer
$26,450,000
Last funding date listed in company snapshot data
Investor Signal
“Y Combinator; HOF Capital; Pioneer Fund; multiple VC and grant backers reported”
